Tait D, McCready V R, Ott R J
Department of Nuclear Medicine, Royal Marsden Hospital, Sutton, Surrey, U.K.
Eur J Cancer Clin Oncol. 1987 Jun;23(6):789-93. doi: 10.1016/0277-5379(87)90280-x.
Technetium-99m-labelled hexamethylpropylene amine oxime (HM-PAO) has been used to investigate tumour perfusion in 11 tumour sites in 8 patients with a variety of histologies. In 8 out of 11 instances single photon emission tomography clearly distinguished between tumour and normal tissues; in 7 cases due to increased HM-PAO uptake and in 1 due to reduced tumour uptake compared with hepatobiliary excretion of HM-PAO in adjacent normal liver. Heterogeneous uptake within individual tumour masses was observed in 3 cases. In 2 where a correlation between the pathology of excised tumour and the scan findings could be made, the findings were consistent with HM-PAO uptake in well-perfused tissue. These preliminary observations suggest that Technetium-99m-HM-PAO may be a valuable clinical technique for displaying patterns of tumour perfusion.
锝-99m标记的六甲基丙烯胺肟（HM-PAO）已被用于研究8例具有多种组织学类型患者的11个肿瘤部位的肿瘤灌注情况。在11例中的8例中，单光子发射断层扫描能清晰区分肿瘤组织和正常组织；7例是由于HM-PAO摄取增加，1例是与相邻正常肝脏中HM-PAO的肝胆排泄相比肿瘤摄取减少。3例在单个肿瘤块内观察到摄取不均匀。在2例能够将切除肿瘤的病理与扫描结果进行关联的病例中，结果与灌注良好组织中HM-PAO的摄取情况一致。这些初步观察结果表明，锝-99m-HM-PAO可能是一种用于显示肿瘤灌注模式的有价值的临床技术。
